查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1782007

减肥药市场，按类型、按剂型、按应用、按配销通路、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Weight Loss Drugs Market, By Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年减肥药市场规模价值 545.0322 亿美元，2025 年至 2032 年的复合年增长率为 19.29%。

减肥药市场-市场动态

提高对肥胖相关健康风险的认识

随着公共卫生运动的兴起、媒体关注度的提高以及持续的医学研究逐渐揭示与肥胖相关的严重健康风险，例如第 2 型糖尿病、心臟病、某些癌症和呼吸问题，越来越多的人开始意识到控制体重的重要性。世界卫生组织 (WHO) 报告称，自 1975 年以来，全球肥胖率几乎增长了两倍，2023 年超过 19 亿成年人被认为超重，其中超过 6.5 亿人被归类为肥胖。这种日益增长的认知促使人们寻找有效的治疗方案，包括减重药物，以帮助减轻这些健康风险。因此，医疗保健提供者越来越多地建议在改变生活方式的同时进行药物治疗。对肥胖相关併发症的认识不断提高，大大增加了全球对减肥药物的需求，促使製药公司开发更安全、更有效的方案来满足这一迫切需求。

例如，

2024年1月，诺和诺德将其旗舰减肥药物Wegovy（索马鲁肽）的供应范围拓展至多个新的国际市场。此次扩张旨在满足全球对有效肥胖治疗药物日益增长的需求，并巩固诺和诺德在减重药物领域的领导地位，帮助全球更多患者管理肥胖及其相关的健康风险。

减肥药市场—关键洞察

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 19.29%

根据类型细分，处方药预计在 2024 年占据最大市场份额

根据剂型细分，注射剂是 2024 年的主要剂型

根据应用细分，食慾抑制是 2024 年的主要应用

根据配销通路细分，零售药局是2024年的主要分销管道

按地区划分，北美是 2024 年的主要收入来源

减肥药市场-細項分析：

全球减肥药市场根据类型、剂型、应用、配销通路和地区进行细分。

市场根据类型分为两类：非处方药 (OTC) 和处方药。处方药在减肥药市场占据主导地位，因为它们的有效性和安全性已得到证实，且需要医疗监督。这些药物通常采用先进的配方，专门针对代谢途径、食慾调节或脂肪吸收，使其在治疗中度至重度肥胖方面更可靠。医生更倾向于开立这些药物，因为它们提供经临床验证的结果，并获得了严格的监管批准。此外，肥胖相关健康併发症的日益增多，也促使医师越来越多地推荐处方减肥药。

根据应用，市场可分为三类：食慾抑制、脂肪阻断及其他。食慾抑制领域占据市场主导地位，食慾抑制剂透过作用于中枢神经系统来减少饥饿感和控制食慾，从而帮助人们减少卡路里摄取并促进持续减肥。这种直接控制食物摄取的方法使食慾抑制剂成为医疗保健提供者和患者的首选。此外，药物配方的最新进展增强了其安全性和有效性，从而提高了患者的依从性和满意度。随着全球肥胖率持续上升，食慾抑制剂仍处于药物体重管理的前沿，推动着市场的显着成长和创新。

减肥药市场—地理洞察

在 2024 年的预测期内，北美将主导全球减肥药市场。

北美是减肥药物市场的主导地区，凭藉其高肥胖率、强大的医疗基础设施以及广泛普及的先进药物，占据了最大的市场份额。尤其是美国，其成年人口中相当一部分被归类为超重或肥胖，在该地区处于领先地位。此外，Wegovy（诺和诺德）和Zepbound（礼来）等减肥药物的早期获准和商业成功也推动了市场的成长。优惠的报销政策、人们对肥胖相关健康风险的日益认识以及积极的政府支持，进一步巩固了北美市场的主导地位。

预计在 2024 年的预测期内，亚太地区的减肥药市场复合年增长率最高。

受快速城市化、久坐不动的生活方式和饮食习惯变化等因素驱动，亚太地区正成为成长最快的市场，肥胖率也随之飙升。中国、印度和韩国等国正经历糖尿病和心血管疾病等肥胖相关疾病的急剧上升。此外，可支配收入的增加、医疗保健服务可近性的改善以及减肥药物治疗的日益普及，也加速了市场需求。此外，不断扩展的医疗保健计划以及政府支持的旨在预防肥胖的公共卫生项目，也支持了亚太地区市场的快速扩张。

减肥药市场-竞争格局：

减重药物市场竞争激烈，发展迅速，这得益于製药巨头、新兴生物技术公司以及肥胖症治疗领域不断增长的研发投入。诺和诺德、礼来、辉瑞、强生和葛兰素史克等领导企业处于领先地位，透过创新、临床试验改进和全球市场扩张来竞争。

诺和诺德凭藉其畅销药物Wegovy（索马鲁肽）占据主导地位，该药物已展现出卓越的临床疗效，并在全球范围内需求旺盛。礼来凭藉Zepbound（替泽帕肽）迅速成为其强大的竞争对手，为第2型糖尿病和减肥提供双重优势。为了满足日益增长的需求，两家公司都在大力投资产能并进入新市场。为了渗透或提升其在这个快速扩张的市场中的地位，辉瑞和葛兰素史克正专注于产品线研发和策略合作。规模较小的生技公司也以客製化的肥胖症治疗方案和创新的治疗手段崭露头角。

市场在功效、安全性、给药便利性和长期疗效等方面的竞争日益激烈，各公司也积极寻求合作、授权交易和收购，以扩大业务范围。随着全球肥胖率持续攀升，减肥药市场的竞争预计将持续激烈，从而促进持续的创新和商业活动。

最新动态：

2025年6月，礼来公司宣布与亚马逊药局达成策略合作，将其减肥药Zepbound（tirzepatide）直接分销给消费者。此举旨在改善患者的可及性和便利性，同时扩大礼来公司在肥胖治疗领域的数位健康影响力。在体重管理疗法需求不断增长的背景下，此次合作有助于该药物的更广泛应用。

2025年4月，诺和诺德收购了以口服给药系统闻名的Emisphere Technologies公司。此次收购旨在改善Wegovy有效成分索马鲁肽的口服製剂，提高患者的依从性和可及性。此举增强了诺和诺德的创新产品线，并支持其在註射和口服减肥疗法领域保持领先地位的策略。

2025年1月，强生与美国生技公司达成合作开发协议，旨在研发用于肥胖管理的双效代谢调节剂。此次合作致力于开发能更安全、长期有效减肥的下一代药物。此举体现了强生在应对全球肥胖和代谢紊乱领域的全新战略兴趣。

2024年10月，葛兰素史克公司（GSK）启动了一项针对中枢神经系统路径的新型食慾抑制剂的第二期临床试验。这项创新是GSK透过首创疗法拓展其代谢健康产品组合的更广泛目标的一部分。本公司旨在开发高效能、患者依从性更高且副作用最小的疗法。

目录

第一章：减肥药市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 减肥药市场片段（按类型）
    • 减肥药市场（按剂型）摘要
    • 减肥药市场片段（按应用）
    • 减肥药市场按配销通路细分
    • 各国减肥药市场概况
    • 减肥药市场（按地区）
  • 竞争洞察

第三章：减肥药主要市场趋势

  • 减肥药市场驱动因素
    • 市场驱动因素的影响分析
  • 减肥药市场限制
    • 市场限制的影响分析
  • 减肥药市场机会
  • 减肥药市场未来趋势

第四章：减肥药物产业研究

  • PESTEL分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：减肥药市场：地缘政治紧张升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：减肥药市场格局

  • 2024年减肥药市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：减肥药市场－依类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 非处方药（OTC）
    • 处方药

第八章：减肥药市场－按剂型

  • 概述
    • 按剂型分類的细分市场份额分析
    • 胶囊
    • 注射
    • 液体
    • 平板电脑

第九章：减肥药市场－依应用

  • 概述
    • 按应用细分市场占有率分析
    • 抑制食慾
    • 脂肪阻断
    • 其他的

第十章：减肥药市场－依配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 网路药局
    • 医院药房
    • 零售药局

第 11 章：减肥药市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美减肥药主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按类型）
    • 北美市场规模及预测（按剂型）
    • 北美市场规模和预测（按应用）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲减肥药主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模及预测（按剂型）
    • 欧洲市场规模和预测，按应用
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区减肥药主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（按类型）
    • 亚太地区市场规模及预测（依剂型划分）
    • 亚太地区市场规模及预测（按应用）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲减肥药主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按类型）
    • 拉丁美洲市场规模及预测（以剂型划分）
    • 拉丁美洲市场规模及预测（按应用）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲减肥药主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模和预测（按类型）
    • MEA 市场规模及预测（以剂型）
    • MEA 市场规模及预测（按应用）
    • MEA 市场规模及预测（依配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：减肥药物产业主要供应商分析

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Eli Lilly and Company
    • Amgen Inc.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • GlaxoSmithKline plc
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Rhythm Pharmaceuticals, Inc.
    • Sanofi SA
    • Structure Therapeutics Inc.
    • Takeda Pharmaceutical Company Limited
    • VIVUS, Inc.
    • Zafgen, Inc.
    • Eisai Co., Ltd.
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5439

REPORT HIGHLIGHT

Weight Loss Drugs Market size was valued at US$ 54,503.22 Million in 2024, expanding at a CAGR of 19.29% from 2025 to 2032.

The Weight Loss Drugs Market is the global industry that develops, makes, and sells pharmaceutical products to help people lose weight. These drugs operate in different ways, like suppressing appetite, blocking fat absorption, or boosting metabolism to manage obesity and overweight issues. The market includes prescription medications, over-the-counter products, and new therapies aimed at tackling the rising rates of obesity-related health problems around the world. The market is growing due to increased awareness of the health risks associated with obesity, more sedentary lifestyles, and a higher demand for effective and safe weight management solutions.

Weight Loss Drugs Market- Market Dynamics

Rising awareness about health risks associated with obesity

With the rise of public health campaigns, increased media attention, and ongoing medical research shining a light on the serious health risks associated with obesity like type 2 diabetes, heart disease, certain cancers, and breathing issues more people are starting to realize just how important it is to manage their weight. The World Health Organization (WHO) reports that since 1975, the global rate of obesity has nearly tripled, with over 1.9 billion adults considered overweight in 2023, and more than 650 million of those classified as obese. This growing awareness is pushing individuals to look for effective treatment options, including weight loss medications, to help mitigate these health risks. Consequently, healthcare providers are increasingly suggesting pharmacological treatments alongside lifestyle changes. This growing consciousness about obesity related complications is significantly boosting the demand for weight loss drugs worldwide, prompting pharmaceutical companies to create safer and more effective options to address this pressing need.

For Instance,

In January 2024, Novo Nordisk expanded the availability of its flagship weight loss drug, Wegovy (semaglutide), to multiple new international markets. This expansion addresses the rising global demand for effective obesity treatments and reinforces Novo Nordisk's leadership in the weight loss drugs sector, aiming to help more patients manage obesity and related health risks worldwide.

Weight Loss Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.29% over the forecast period (2025-2032)

Based on type segmentation, prescription drugs were predicted to show maximum market share in the year 2024

Based on dosage form segmentation, injections was the leading dosage form in 2024

Based on application segmentation, appetite suppression was the leading application in 2024

Based on distribution channel segmentation, retail pharmacy was the leading distribution channels in 2024

On the basis of region, North America was the leading revenue generator in 2024

Weight Loss Drugs Market- Segmentation Analysis:

The global weight loss drugs market is segmented on the basis of type, dosage form, application, distribution channel, and region.

The market is divided into two categories based on type: Over-the-counter drugs (OTC) and prescription drugs. The Prescription Drugs segment dominates the Weight Loss Drugs Market due to their proven effectiveness and safety profile, which require medical supervision. These drugs often involve advanced formulations that specifically target metabolic pathways, appetite regulation, or fat absorption, making them more reliable for treating moderate to severe obesity. Physicians prefer prescribing these medications because they provide clinically validated results and are supported by rigorous regulatory approvals. Additionally, the growing prevalence of obesity-related health complications is driving increased physician recommendation of prescription weight loss drugs.

The market is divided into three categories based on application: appetite suppression and fat blocking and others. The appetite suppression sector dominates the market and Appetite suppressants work by targeting the central nervous system to reduce feelings of hunger and control cravings, which helps individuals consume fewer calories and promotes sustained weight loss. This direct approach to managing food intake makes appetite suppressants a preferred choice for both healthcare providers and patients. Moreover, recent advancements in drug formulations have enhanced their safety profiles and effectiveness, increasing patient adherence and satisfaction. With obesity rates continuing to rise globally, appetite suppressants remain at the forefront of pharmacological weight management, driving significant market growth and innovation.

Weight Loss Drugs Market- Geographical Insights

North America dominates the global weight loss drugs market during the forecast period in 2024.

North America is dominating region in the weight loss drugs market, accounting for the largest market share due to its high prevalence of obesity, strong healthcare infrastructure, and widespread access to advanced medications. The United States, in particular, leads the region with a significant portion of the adult population classified as overweight or obese. Additionally, the early approval and commercial success of weight loss drugs such as Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) have boosted market growth. Favourable reimbursement policies, growing awareness about obesity-related health risks, and active government support further contribute to North America's market dominance.

Asia Pacific is estimated to register the highest CAGR in the weight loss drugs market during the forecast period in 2024.

Asia-Pacific region is emerging as the fastest-growing market, driven by rapid urbanization, sedentary lifestyles, and dietary changes leading to a surge in obesity rates. Countries like China, India, and South Korea are experiencing a sharp rise in obesity-related diseases such as diabetes and cardiovascular disorders. Alongside this, increasing disposable incomes, improved access to healthcare, and growing acceptance of pharmaceutical treatments for weight loss are accelerating demand. Moreover, expanding healthcare initiatives and government-backed public health programs aimed at obesity prevention are supporting the market's rapid expansion across Asia-Pacific.

Weight Loss Drugs Market- Competitive Landscape:

The weight loss drugs market is highly competitive and rapidly evolving, driven by a mix of pharmaceutical giants, emerging biotech firms, and growing R&D investments in obesity treatment. Leading players such as Novo Nordisk, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline are at the forefront, competing through innovation, clinical trial advancements, and global market expansion.

With its popular medication Wegovy (semaglutide), which has demonstrated excellent clinical outcomes and great demand worldwide, Novo Nordisk presently holds a dominant market share. With Zepbound (tirzepatide), Eli Lilly has swiftly become a formidable competitor, providing dual-action advantages for type 2 diabetes and weight loss. To keep up with the increasing demand, both businesses are making significant investments in manufacturing capacity and entering new markets. To penetrate or improve their positions in this rapidly expanding market, Pfizer and GSK are concentrating on pipeline research and strategic partnerships. Smaller biotech businesses are also making an appearance with customized obesity treatments and innovative methods of action.

The market is witnessing increased competition in terms of efficacy, safety profiles, dosing convenience, and long-term outcomes, with companies also pursuing partnerships, licensing deals, and acquisitions to expand their reach. As obesity rates continue to climb globally, the competitive intensity in the weight loss drugs market is expected to remain strong, fostering ongoing innovation and commercial activity.

Recent Developments:

In June 2025, Eli Lilly announced a strategic collaboration with Amazon Pharmacy to distribute its weight loss drug Zepbound (tirzepatide) directly to consumers. The move aims to improve patient access and convenience, while expanding Eli Lilly's digital health footprint in the obesity treatment space. This partnership supports broader adoption amid rising demand for weight management therapies.

In April 2025, Novo Nordisk acquired Emisphere Technologies, a company known for oral drug delivery systems. This acquisition is intended to improve oral formulations of semaglutide, the active ingredient in Wegovy, enhancing patient compliance and accessibility. It strengthens Novo Nordisk's innovation pipeline and supports its strategy to lead in both injectable and oral weight loss therapies.

In January 2025, Johnson & Johnson entered into a co-development partnership with a U.S.-based biotech firm to create dual-acting metabolic modulators for obesity management. The collaboration focuses on developing next-generation drugs that offer safer, long-term weight loss. This move reflects J&J's renewed strategic interest in addressing global obesity and metabolic disorders.

In October 2024, GlaxoSmithKline (GSK) launched Phase 2 clinical trials for a novel appetite suppressant targeting central nervous system pathways. This innovation is part of GSK's broader goal to expand its metabolic health portfolio with first-in-class treatments. The company aims to develop therapies that offer high efficacy with improved patient compliance and minimal side effects.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL WEIGHT LOSS DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Eli Lilly and Company
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd (Roche Holding AG)
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Structure Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS, Inc.
  • Zafgen, Inc.
  • Eisai Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Others

GLOBAL WEIGHT LOSS DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Over-the-counter drugs (OTC)
  • Prescription Drugs

GLOBAL WEIGHT LOSS DRUGS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Injections
  • Liquids
  • Tablets

GLOBAL WEIGHT LOSS DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Appetite Suppression
  • Fat Blocking
  • Others

GLOBAL WEIGHT LOSS DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

GLOBAL WEIGHT LOSS DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Weight Loss Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Weight Loss Drugs Market Snippet by Type
    • 2.1.2. Weight Loss Drugs Market Snippet by Dosage Form
    • 2.1.3. Weight Loss Drugs Market Snippet by Application
    • 2.1.4. Weight Loss Drugs Market Snippet by Distribution Channel
    • 2.1.5. Weight Loss Drugs Market Snippet by Country
    • 2.1.6. Weight Loss Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Weight Loss Drugs Key Market Trends

  • 3.1. Weight Loss Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Weight Loss Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Weight Loss Drugs Market Opportunities
  • 3.4. Weight Loss Drugs Market Future Trends

4. Weight Loss Drugs Industry Study

  • 4.1. PESTEL Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Weight Loss Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Weight Loss Drugs Market Landscape

  • 6.1. Weight Loss Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Weight Loss Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Over-the-counter drugs (OTC)
    • 7.1.3. Prescription Drugs

8. Weight Loss Drugs Market - By Dosage Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 8.1.2. Capsules
    • 8.1.3. Injections
    • 8.1.4. Liquids
    • 8.1.5. Tablets

9. Weight Loss Drugs Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Appetite Suppression
    • 9.1.3. Fat Blocking
    • 9.1.4. Others

10. Weight Loss Drugs Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Online Pharmacy
    • 10.1.3. Hospital Pharmacy
    • 10.1.4. Retail Pharmacy

11. Weight Loss Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Weight Loss Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Weight Loss Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Weight Loss Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Weight Loss Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Weight Loss Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Weight Loss Drugs Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Eli Lilly and Company
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca
    • 12.2.4. F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • 12.2.5. GlaxoSmithKline plc
    • 12.2.6. Ionis Pharmaceuticals, Inc.
    • 12.2.7. Johnson & Johnson
    • 12.2.8. Merck & Co., Inc.
    • 12.2.9. Novartis AG
    • 12.2.10. Teva Pharmaceutical Industries Ltd.
    • 12.2.11. Pfizer Inc.
    • 12.2.12. Rhythm Pharmaceuticals, Inc.
    • 12.2.13. Sanofi S.A.
    • 12.2.14. Structure Therapeutics Inc.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. VIVUS, Inc.
    • 12.2.17. Zafgen, Inc.
    • 12.2.18. Eisai Co., Ltd.
    • 12.2.19. Boehringer Ingelheim International GmbH
    • 12.2.20. Currax Pharmaceuticals LLC
    • 12.2.21. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us